Jennison Associates
MRNS

Jennison Associates’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Jennison Associates’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,469,285
Closed -$1.72M – 655
2024
Q2 		$1.72M Sell
1,469,285
-1,496,598
-50% -$3.74M ﹤0.01% 454
2024
Q1 		$26.8M Buy
2,965,883
+6,722
+0.2% +$65.3K 0.02% 311
2023
Q4 		$32.2M Buy
2,959,161
+3,818
+0.1% +$28.6K 0.02% 262
2023
Q3 		$23.8M Buy
2,955,343
+1,089,913
+58% +$9.07M 0.02% 288
2023
Q2 		$20.3M Buy
+1,865,430
New +$16M 0.02% 316
2019
Q3 		– Sell
-1,061,791
Closed -$17.6M – 700
2019
Q2 		$17.6M Sell
1,061,791
-70,040
-6% -$1.22M 0.02% 373
2019
Q1 		$18.9M Sell
1,131,831
-6,859
-0.6% -$98.8K 0.02% 361
2018
Q4 		$13.1M Buy
1,138,690
+663,059
+139% +$13.4M 0.01% 409
2018
Q3 		$19M Sell
475,631
-213,708
-31% -$6.08M 0.02% 405
2018
Q2 		$19.5M Buy
689,339
+5,433
+0.8% +$120K 0.02% 408
2018
Q1 		$10.4M Buy
683,906
+9,768
+1% +$233K 0.01% 453
2017
Q4 		$22M Buy
674,138
+272,455
+68% +$7.34M 0.02% 389
2017
Q3 		$9.43M Buy
401,683
+198,767
+98% +$2.23M 0.01% 488
2017
Q2 		$1.11M Buy
202,916
+105,400
+108% +$570K ﹤0.01% 570
2017
Q1 		$690K Buy
+97,516
New +$524K ﹤0.01% 593

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jennison Associates's MRNS Position: Q3 2024 in Review

Jennison Associates sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 1,469,285 shares — an estimated $1.72M sold.

Jennison Associates first reported a position in MRNS in Q1 2017 and held it in 15 quarters. The position peaked at $32.2M in Q4 2023. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Jennison Associates reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Jennison Associates sold 1,469,285 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $1.72M.
  • Jennison Associates first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 15 quarters.
  • Jennison Associates's Marinus Pharmaceuticals, Inc position peaked at $32.2M in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Jennison Associates's 13F filing for Q3 2024, filed 8 Nov 2024.